Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5368 - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Cancer Biology;  Immunotherapy;  Thoracic Malignancies


Moshe Giladi


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


M. Giladi1, T. Voloshin2, O. Talyitzhaki3, U. Weinberg4, E.D. Kirson3

Author affiliations

  • 1 Preclinical, Novocure, 30032 - Haifa/IL
  • 2 Preclinical, Novocure, Haifa/IL
  • 3 Research And Development, Novocure, Haifa/IL
  • 4 Clincal Development, Novocure, 6039 - Luzern/CH


Abstract 5368


Tumor Treating Fields (TTFields) are an effective anti-neoplastic treatment modality delivered via non-invasive application of low intensity, intermediate frequency, alternating electric fields. TTFields is approved for the treatment of both newly diagnosed and recurrent glioblastoma. TTFields interrupt mitosis in cancer cells by disrupting microtubules and septin filaments, which play key roles in mitosis. The mitotic effects of TTFields include abnormal chromosome segregation that trigger different forms of cell death. We evaluated TTFields’ effect on immunogenic cell death and its efficacy when combined with an immune checkpoint inhibitor (αPD1) in NSCLC.


Murine Lewis lung carcinoma (LLC) cells were treated with TTFields using the inovitroTM system. Levels of cell surface calreticulin (CRT) and intracellular ATP levels were evaluated using flow cytometry. High mobility group box 1 (HMGB1) secretion was measured using an ELISA assay. Mice inoculated with LLC cells were treated with isotype control, TTFields, αPD-1, or TTFields + αPD-1. Tumor volume monitoring and intra-tumor immune cell profiling were performed.


TTFields induced elevated cell surface expression of CRT, decreased ATP levels, and promoted HMGB1 secretion. In vivo, the combined treatment of TTFields + α-PD-1 led to a significant decrease in lung tumor volume compared to all three other groups (P 


Our results demonstrate that TTFields treatment potentiates immunogenic cell death in NSCLC cancer cells. Combining TTFields with specific immunotherapies such as anti-PD-1 may enhance antitumor immunity and result in increased tumor control. A phase III clinical study on TTFields in combination with either PD-1 inhibitors or docetaxel in NSCLC is underway.

Clinical trial identification

Legal entity responsible for the study





M. Giladi, T. Voloshin, O. Talyitzhaki, U. Weinberg, E.D. Kirson: Novocure employee.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.